Abaloparatide - Qilu Pharmaceutical
Alternative Names: Abaloparatide injection - Qilu PharmaceuticalLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Qilu Pharmaceutical
- Class Calcium regulators; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteoporosis
Most Recent Events
- 31 Dec 2024 Preclinical trials in Osteoporosis in China (Parenteral)
- 31 Dec 2024 Qilu Pharmaceutical in collaboration with The Affiliated Hospital of Qingdao University plans a phase I trial in healthy adult volunteers in China in January 2025 (Parenteral, Injection) (NCT06753864)